Objective: To evaluate the effects of simvastatin only or combined with continuous transdermal hormone replacement therapy (HRT) on the serum lipid profile in hypercholesterolaemic women.
Material And Methods: The study population consisted of 75 women after menopause, ranging in age from 45 to 62. The patients were divided into five groups: group I--women receiving HRT (Systen Sequi, Cilag); group II--HRT + statin (Systen Sequi, Cilag + Zocor, MSD); group III--HRT (Systen Conti, Cilag); group IV--HRT + statin (Systen Conti, Cilag + Zocor, MSD) and group V--statin only (Zocor, MSD). Before and after 3 and 6 months therapy serum total cholesterol (TC), triglycerides (TG), HDL-cholesterol (HDL-C) and LDL-cholesterol (LDL-C) was measured.
Results: The combination of simvastatin + HRT or simvastatin only decreased significantly TC and LDL-C, and increased HDL-C levels at 3 months (groups II, IV and V). A comparative analysis revealed that HRT effect on TC, LDL-C and HDL-C was significantly observed after 6 months (group I and III). TG levels significantly decreased after 6 months of therapy (simvastatin + HRT) in groups II and IV.
Conclusions: The combination of simvastatin and HRT seems to be more effective than simvastatin only in the treatment of hypercholesterolaemia in women.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Evaluation of the role of metabolizing enzymes and transporter variants in ezetimibe pharmacokinetics.
Front Pharmacol
October 2024
Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria La Princesa (IIS-Princesa), Madrid, Spain.
Article Synopsis
- Ezetimibe is a drug that helps reduce cholesterol levels by blocking its absorption in the intestines, but there are currently no established pharmacogenetic guidelines for its use.
- The study involved 96 healthy participants from different trials and focused on 49 genetic variants in 22 genes to determine their impact on ezetimibe's effects.
- Although no strong links were found between genetic variants and ezetimibe's metabolism, some variants showed potential significance in further analyses, suggesting the need for more research in the future.
Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model.
Br J Gen Pract
March 2024
Health Economics and Policy Research Unit, Wolfson Institute of Population Health, Queen Mary University of London, London; associate professor and senior health economist, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Background: UK cardiovascular disease (CVD) incidence and mortality have declined in recent decades but socioeconomic inequalities persist.
Aim: To present a new CVD model, and project health outcomes and the impact of guideline-recommended statin treatment across quintiles of socioeconomic deprivation in the UK.
Design And Setting: A lifetime microsimulation model was developed using 117 896 participants in 16 statin trials, 501 854 UK Biobank (UKB) participants, and quality-of-life data from national health surveys.
Randomized phase II clinical trial of ruxolitinib plus simvastatin in COVID19 clinical outcome and cytokine evolution.
Front Immunol
May 2023
Faculty of Experimental Sciences, Universidad Francisco de Vitoria, Madrid, Spain.
Background: Managing the inflammatory response to SARS-Cov-2 could prevent respiratory insufficiency. Cytokine profiles could identify cases at risk of severe disease.
Methods: We designed a randomized phase II clinical trial to determine whether the combination of ruxolitinib (5 mg twice a day for 7 days followed by 10 mg BID for 7 days) plus simvastatin (40 mg once a day for 14 days), could reduce the incidence of respiratory insufficiency in COVID-19.
Donor Simvastatin Treatment in Liver Transplantation: Post Hoc Analysis of a Randomized Placebo-controlled Trial With Long-term Follow-up.
Transplantation
April 2023
Translational Immunology Research Program and Transplantation Laboratory, University of Helsinki, Helsinki, Finland.
A retrospective study: efficacy of an originator versus a generic formulation of simvastatin in patients who suffer from hyperlipidaemia.
Cardiovasc J Afr
May 2024
Pharmaceutics, Cape Town, South Africa.
Background: South Africa is home to a multi-ethnic society with a large range of cultures and lifestyles. Cardiovascular disease is a major cause of morbidity and mortality. South Africa is known to have one of the highest incidence rates of hypercholesterolaemia in the world, especially among the Caucasian population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!